Portfolio company
Predicta Biosciences
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops blood-based genomic diagnostic tests for clinicians and pharmaceutical partners to monitor and treat blood cancers.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Predicta
Predicta develops blood-based molecular diagnostic tests that provide genomic and immune insights for clinicians to guide treatment for patients with blood cancers.
LiquidCell Dx
This company develops blood-based liquid biopsy tests for tumor microenvironment profiling to help pharmaceutical companies and clinical partners predict cancer therapy responses.
Foresight Diagnostics
This company develops liquid biopsy tests to detect minimal residual disease in cancer patients for biopharmaceutical companies and healthcare providers.
Delfi Diagnostics
This company develops blood-based liquid biopsy tests for early cancer detection and treatment monitoring for healthcare providers, health systems, and biopharmaceutical partners.
Cambridge Cancer Genomics
This company develops precision oncology software for clinicians to monitor treatment response and detect cancer relapse using genomic data and blood samples.
Oncobit
This company develops precision diagnostic assays and cloud-based monitoring software for clinicians to track cancer markers and therapy response in oncology patients.
Infiniplex
This company develops liquid biopsy solutions using blood tests to monitor genetic biomarkers for cancer screening and precision oncology decisions for healthcare providers.
Precede Biosciences
The company develops an epigenomic liquid biopsy platform for biopharmaceutical companies and researchers to profile gene expression and disease biology from blood samples.